Skip to content
Back to TSHA

Taysha Gene Therapies, Inc.

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 17, 2025
Transactions
12
Purchases
0
Sales
12
Purchase value
$0.00
Sale value
$6.66M

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

Sukumar NagendranDirector · President and Head of R&D
4Rule 10b5-1 plan disclosed
Filed Jul 10, 2026Period of report Jul 10, 20260001665124-26-000013
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 10, 2026
Common StockF1F2200,000$6.24$1.25M936,410Direct
Filing footnotes · 2
  1. F1This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025.
  2. F2The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.99 to $6.52 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open on SEC EDGAR
Sukumar NagendranDirector · President and Head of R&D
4Rule 10b5-1 plan disclosed
Filed Apr 13, 2026Period of report Apr 10, 20260001665124-26-000011
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleApr 10, 2026
Common StockF1F2200,000$4.46$892.00K1,136,410Direct
Filing footnotes · 3
  1. F1This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025.
  2. F2The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.335 to $4.625 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F325% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
Open on SEC EDGAR
Kamran AlamCHIEF FINANCIAL OFFICER
4
Filed Feb 6, 2026Period of report Feb 4, 20260001793412-26-000012
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 4, 2026
Common StockF11,655$4.52$7.48K1,442,131Direct
Filing footnotes · 1
  1. F1The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.
Open on SEC EDGAR
Kamran AlamCHIEF FINANCIAL OFFICER
4
Filed Jan 27, 2026Period of report Jan 23, 20260001793412-26-000008
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 26, 2026
Common StockF1F323,849$4.61$109.94K1,443,786Direct
SaleJan 23, 2026
Common StockF1F278,968$4.75$375.10K1,467,635Direct
Filing footnotes · 3
  1. F1The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.
  2. F2The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.635 to $4.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).
  3. F3The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.505 to $4.715 inclusive.
Open on SEC EDGAR
Sukumar NagendranDirector · President and Head of R&D
4
Filed Jan 27, 2026Period of report Jan 23, 20260001665124-26-000008
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 26, 2026
Common StockF1F326,918$4.61$124.09K1,317,389Direct
SaleJan 23, 2026
Common StockF1F289,132$4.75$423.38K1,344,307Direct
Filing footnotes · 3
  1. F1The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.
  2. F2The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.635 to $4.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).
  3. F3The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.505 to $4.715 inclusive.
Open on SEC EDGAR
Sean P. NolanDirector · Chief Executive Officer
4
Filed Jan 27, 2026Period of report Jan 23, 20260001569926-26-000008
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 26, 2026
Common StockF1F341,312$4.61$190.45K2,908,257Direct
SaleJan 23, 2026
Common StockF1F2136,789$4.75$649.75K2,949,569Direct
Filing footnotes · 4
  1. F1The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.
  2. F2The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.635 to $4.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).
  3. F3The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.505 to $4.715 inclusive.
  4. F4The securities are held by Nolan Capital, LLC (the "LLC"). The Reporting Person is the President of the LLC and has shared voting and investment power with respect to the shares held by the LLC.
Open on SEC EDGAR
Sukumar NagendranDirector · President and Head of R&D
4Rule 10b5-1 plan disclosed
Filed Jan 14, 2026Period of report Jan 12, 20260001665124-26-000002
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 12, 2026
Common StockF1F2200,000$4.71$942.00K1,006,439Direct
Filing footnotes · 6
  1. F1This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025.
  2. F2The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.565 to $4.92 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3Represents a restricted stock unit ("RSU") award. The RSUs will vest in four equal annual installments beginning on January 12, 2027, subject to the Reporting Person's continuous service through each applicable vesting date.
  4. F4The shares underlying the option vested or shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date.
  5. F525% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
  6. F625% of the total number of shares underlying the option shall vest and become exercisable on January 12, 2027 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
Open on SEC EDGAR
Sukumar NagendranDirector · President and Head of R&D
4
Filed Dec 1, 2025Period of report Nov 28, 20250001665124-25-000003
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 1, 2025
Common StockF2260,047$4.51$1.17M1,006,439Direct
SaleNov 28, 2025
Common StockF1110,125$4.75$523.09K1,006,439Direct
Filing footnotes · 4
  1. F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.7248 to $4.8348 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2).
  2. F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.42 to $4.63 inclusive.
  3. F3The shares underlying the option vested or shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date.
  4. F425% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.